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ABSTRACT Among Gram-negative bacteria, carbapenem-resistant infections pose a
serious and life-threatening challenge. Here, the CRACKLE network reports a sentinel
detection and characterization of a carbapenem-resistant Klebsiella pneumoniae ST147
isolate harboring blaNDM-5 and blaOXA-181 from a young man who underwent ab-
dominal surgery in India. blaNDM-5 was located on an IncFII plasmid of 90 kb,
whereas blaOXA-181 was chromosomally encoded. Resistome and genome analysis
demonstrated multiple copies of the transposable element IS26 and a “hot-spot re-
gion” in the IncFII plasmid.
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Carbapenem-resistant Klebsiella pneumoniae (CR Kp) infections are among the mostproblematic clinical challenges worldwide, since few antimicrobials retain activity
against them, and they are associated with high morbidity and mortality (1, 2). The New
Delhi metallo-beta-lactamase (NDM-1) was first identified in 2008 (3). blaNDM has
emerged as a major global health challenge not only because of its ability to confer
resistance to nearly all beta-lactam antibiotics but also because of its rapid spread
worldwide. At present, 16 blaNDM-5 variants are reported in 40 countries, and it is
endemic in several areas (Southeast Asia, the Balkans, and the Middle East) (4). The
NDM-5 variant differs from NDM-1 at amino acid positions Val88Leu and Met154Leu,
and this metallo-beta-lactamase was first identified in a multidrug-resistant Escherichia
coli ST648 isolate from a patient in the United Kingdom who had a recent history of
hospitalization in India (5). NDM-5 has since been detected in Algeria Spain, Japan,
Australia, China, and Egypt (6–10).
The OXA-48 beta-lactamase was initially identified in a K. pneumoniae isolate from
a patient residing in Istanbul, Turkey, in 2001 (11). Soon after, the gene encoding this
carbapenemase (the “phantom menace”) rapidly disseminated through Turkish hospi-
tals, with outbreaks in the main cities of the country reaching endemic levels (12, 13).
Since then, 11 variants of blaOXA-48-like have been designated and have spread to the
Middle East, North Africa, and Europe. In addition, several nosocomial outbreaks were
reported in Mediterranean countries, including France, Spain, Lebanon, Israel, Tunisia,
Morocco, and Malta, and have reached an endemic situation (14). OXA-181, a variant of
OXA-48 that differs by four amino acid substitutions (Thr104Ala, Asn110Asp, Glu175Gln,
and Ser179Ala), was initially identified in Enterobacter cloacae and K. pneumoniae
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isolates that were recovered in 2007 in India (15). Since then, OXA-181-producing
Enterobacteriaceae were reported in several other countries on the Indian subcontinent,
including Bangladesh, Sri Lanka, and Nepal (16, 17), followed by Canada, France, the
Netherlands, New Zealand (in a K. pneumoniae isolate from a patient from Nepal),
Norway (in a patient from Romania), Oman, Romania, Singapore, South Africa, and the
United Kingdom (in a patient from India) (18).
Herein, we report a K. pneumoniae isolate harboring blaNDM-5 and blaOXA-181 and a
paired isolate from the same patient exhibiting highly plastic genomic regions associ-
ated with the IS26 insertion element involved in the loss of blaNDM-5 and several other
resistance determinants. These isolates were detected as part of a surveillance network
dedicated to characterizing the K. pneumoniae carbapenemase (KPC) epidemic in the
United States and elsewhere.
A young man underwent sleeve gastrectomy for management of obesity in India in
2014. The surgery was complicated by a postoperative anastomotic leak, and the
patient was transferred to a U.S. hospital a month after surgery. An abdominal washout
was required, and the patient was placed on bowel rest and started on total parenteral
nutrition. However, he developed an enterocutaneous fistula and was transferred to
one of the hospitals participating in CRACKLE (The Consortium on Resistance against
Carbapenems in Klebsiella pneumoniae), a prospective, multicenter, observational study
in the Great Lakes Region of the United States (2), for a Roux-en-Y gastric bypass
procedure and resection of the fistula. This surgery was performed 4 months after his
initial operation. Cultures sent from abdominal fluid revealed a carbapenem-resistant K.
pneumoniae strain (CR Kp-1) (Table 1) and Candida albicans. The patient was initially
treated with ciprofloxacin, metronidazole, and micafungin. After CR Kp-1 was con-
firmed, ciprofloxacin was switched to tigecycline. He remained febrile, and a repeat
abdominal computed tomography scan revealed persistent fluid collections, which
were drained percutaneously. Cultures from this procedure again revealed a
carbapenem-resistant K. pneumoniae strain (CR Kp-2) (Table 1). He was treated for a
total of 16 days with tigecycline. His symptoms resolved, and he was discharged in
stable condition and off of antibiotics after a 28-day admission.
The Check MDR CT103 XL assay (Check-Points, Wageningen, Netherlands) was used
to detect beta-lactamase genes, including extended-spectrum beta-lactamases (blaSHV
and blaTEM ESBLs), plasmid-mediated AmpCs, and carbapenemases, including blaKPC,
blaNDM, blaVIM, blaIMP, blaOXA-48-like, blaGES, blaGIM, blaSPM, blaOXA-23-like, blaOXA-24/40-like,
blaOXA-48-like. CR Kp-1 contained blaNDM, blaOXA-48-like, blaCTX-M-15-like, blaSHV-WT, and
blaTEM-WT. CR Kp-2 contained blaOXA-48-like, blaCTX-M-15-like, and blaSHV-WT. PCR amplifi-
cation and sequencing performed to identify blaNDM and blaOXA-48-like variants con-
TABLE 1MICs for CR Kp-1 and CR Kp-2, evaluated by Etest
Antibiotic
MIC (mg/liter) for:
CR Kp-1 CR Kp-2
Tigecycline 0.5 0.5
Amikacin 256 2
Gentamicin 256 2
Ampicillin-sulbactam 256 256
Piperacillin/tazobactam 256 256
Ceftazidime/avibactam 256 0.5
Ceftazidime 256 48
Cefepime 256 96
Ceftriaxone 32 32
Cefotaxime 32 32
Ertapenem 32 32
Imipenem 32 4
Meropenem 32 24
Doripenem 32 8
Polymyxin Ba 0.5 1
aPolymyxin B susceptibility was evaluated by broth microdilution.
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firmed that CR Kp-1 carried blaNDM-5 and blaOXA-181, whereas CR Kp-2 carried only
blaOXA-181.
Conjugation experiments were performed using K. pneumoniae clinical strains as
donors and the azide-resistant E. coli J53 as a recipient; however, transconjugants were
not obtained. Therefore, plasmid DNA was extracted and electroporated into E. coli
DH10B (19). Transformants were selected on ampicillin-containing lysogeny broth agar,
and the presence of blaNDM-5 and blaOXA-181 was confirmed by PCR amplification.
Plasmid characterization on CR Kp-1 and CR Kp-2 isolates, as well as on transformants,
was performed by PCR-based replicon typing using the PCR-based replicon typing kit
(Diatheva, Fano, PU, Italy) following the manufacturer’s instructions. Only an IncFII
amplicon was obtained for both strains and transformants. S1 nuclease pulsed-field gel
electrophoresis (PFGE) followed by Southern hybridization with blaNDM-5, blaOXA-181,
and IncFII replicon probes for clinical strains and transformants (see Fig. S1 in the
supplemental material) and I-CeuI PFGE followed by Southern hybridization with
blaOXA-181 and 16S probes for clinical strains (see Fig. S2 in the supplemental material)
suggested that blaNDM-5 was located on an IncFII plasmid of 90 kb, while blaOXA-181
was encoded chromosomally (20, 21).
Draft whole-genome sequences were obtained from Illumina paired-end reads. Use
of ResFinder (https://cge.cbs.dtu.dk/services/ResFinder/) with assemblies as input con-
firmed that CR Kp-2 possesses a resistome smaller than that of CR Kp-1 (Table 2) (22).
Likewise, BLAST revealed that for CR Kp-1, blaNDM-5 was localized on an IncFII plasmid
of 90 kb (99% similarity with pCC1409, a blaNDM-5-harboring IncFII plasmid from a K.
pneumoniae ST147 isolated in Poland; KT725789.1) (Fig. 1A). Interestingly, this same
plasmid was present in CR Kp-2; however, it was slightly smaller due to the loss of an
25-kb region, including not only blaNDM-5 but also several other resistance determi-
nants (e.g., blaTEM-1, mphA, ermB, dfrA12, aadA2, and rmtB) (Fig. 1A). ISFinder (https://
www-is.biotoul.fr) showed the presence of multiple transposable elements, including
IS26, distributed along the above-mentioned region (Fig. 1B) (23). Of note, the finding
of rmtB is manifested by the difference in susceptibility to aminoglycosides (256 versus
2 mg/liter) (Table 1). In addition, the presence of numerous resistance determinants
may indicate that this is a “hot-spot region.” Given the replicative transposition mech-
anism of IS26 and its previously shown critical role in the mobilization and reorgani-
zation of antibiotic resistance genes in Gram-negative bacteria, we hypothesize that the
excision of this region might have been aided by IS26 (24, 25).
ISEcp1 was identified upstream of blaOXA-181, as previously described (18); I-CeuI
PFGE and probe hybridization suggested that this carbapenemase was chromosomally
located in both clinical strains. Interestingly, transformation experiments revealed that
blaOXA-181 was also carried by a plasmid on the CR Kp-2 E. coli transformant, which,
based on size and IncFII probe hybridization, is the same plasmid that lost the
above-mentioned 25-kb blaNDM-5-harboring region. This might indicate a transposi-
tion event aided by the flanking ISEcp1 accompanying this gene, highlighting the
plasticity of this plasmid to incorporate or lose genes (Fig. S1 and S2 in the supple-
mental material).
In the United States, blaNDM has been circulating since 2010 (26), whereas blaOXA-48
was imported in 2012 by patients who were initially hospitalized in Saudi Arabia and
India (27). The rapid and widespread dissemination of blaOXA-181 throughout Southeast
Asia, the recent finding of blaOXA-181 (associated with the ISEcp1 mobile genetic
element) in the chromosome of a wastewater Shewanella xiamenensis isolate (28), and
TABLE 2 Resistome of CR Kp-1 and CR Kp-2
Strain
Genome
size (bp)
No. of
contigs Resistance determinants
CR Kp-1 5,608,317 87 oqxA, oqxB, blaSHV-11, fosA, rmtF, aacA4, aac(6=)Ib-cr, qnrB12, dfrA14, blaOXA-181, ARR-2, blaCTX-M-15, mph(A), sul1,
erm(B), dfrA12, aadA2, rmtB, blaTEM-1, blaNDM-5
CR Kp-2 5,587,222 79 oqxA, oqxB, blaSHV-11, fosA, rmtF, aacA4, aac(6=)Ib-cr, qnrB12, dfrA14, blaOXA-181, ARR-2, blaCTX-M-15
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the recognition that most cases outside of this area of the world are from patients
that had a recent travel history to Southeast Asia and the Asian Pacific region
suggest that this is the likely place of origin for blaOXA-181 and an important
reservoir of this carbapenemase gene. Multilocus sequence typing (MLST) (http://
www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html) revealed that CR
Kp-1 and CR Kp-2 both belong to ST147. A K. pneumoniae isolate belonging to the same
ST type (ST147) and carrying an IncFII plasmid with blaOXA-181 and blaNDM-5 was
previously reported in South Korea from a patient transferred from a tertiary care
hospital in Abu Dhabi, United Arab Emirates (29). However, the first report of a K.
pneumoniae isolate harboring blaOXA-181 and blaNDM-5 occurred in Singapore in 2013
and was isolated from the urine of a patient that was transferred from Bangladesh (16).
Another isolate harboring both carbapenemase genes was described in Egypt; how-
ever, it was an E. coli that carried each gene on a different plasmid (30). In the United
States, a K. pneumoniae isolate carrying blaNDM-1 and blaOXA-232 was reported in another
patient transferred from India (31). However, blaNDM-5 and blaOXA-181 have been
reported only once before in the same patient but in different E. coli isolates (32).
In summary we describe the occurrence of two clinically important carbapenemases
(the “evil twins”), blaOXA-181 (chromosomally encoded) and blaNDM-5 (plasmid encoded),
FIG 1 (A) Coverage of Illumina reads from K. pneumoniae isolates CR Kp-1 and CR Kp-2 mapped using Bowtie2 (33) across the reference IncFII plasmid pCC1409
(KT725789.1). (B) Organization of the 25-kb blaNDM-5-containing region of the IncFII plasmid present only in CR Kp-1. This entire region was excised out of the
IncFII plasmid present in CR Kp-2.
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in a carbapenem-resistant K. pneumoniae clinical isolate in the United States. Our results
also underscore the ability of ceftazidime/avibactam to indicate the presence of
metallo-beta-lactamases when carbapenem-resistant isolates show resistance to this
combination. These findings underscore the importance of molecular surveillance
programs such as CRACKLE that characterize resistant strains and highlight the emer-
gence of novel genotypes in the United States.
Accession number(s). The nucleotide sequence of the draft genomes for CR Kp-1
(1699_2676) and CR Kp-2 (1699_2677) were deposited in GenBank under accession
numbers NZ_MPYK00000000.1 and NZ_MPYL00000000.1, respectively.
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